Ashlene McKay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashlene McKay has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Chia Wei Teoh
Division of Pediatric Nephrology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
2 shared publications - Christoph Licht
The Hospital for Sick Children
2 shared publications Allison B. Dart
Department of Pediatrics and Child Health, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
1 shared publication- Amrit Kirpalani
Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University , London, Ontario
1 shared publication Andrew M. South
Department of Pediatrics, Brenner Children's, Wake Forest University School of Medicine, Winston-Salem, NC, USA
1 shared publicationCal H. Robinson
Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada
1 shared publication
Latest Publications
- 15 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1767-1779
Challenging Clinical Practice Guideline Definitions in Childhood Nephrotic Syndrome
Key Points: Three quarters of children with steroid-resistant nephrotic syndrome respond to other immunosuppression and have good kidney outcomes. Children classified as frequently relapsing by International Pediatric Nephrology Association versus Kidney Disease Improving Global Outcomes criteria have similar relapse rates and risk of CKD. These findings support defining treatment resistance by response to any immunosuppression and implementing the International Pediatric Nephrology Association criteria for frequent relapses. Background: In childhood nephrotic syndrome, definitions of immunosuppression response, frequently relapsing nephrotic syndrome (FRNS), and long-term remission are conflicting and based on limited evidence. Our goal was to define treatment response, FRNS, and long-term remission on the basis of associated disease outcomes. Methods: We included children (6 months–18 years) diagnosed with nephrotic syndrome between 1993 and 2023 in combined Canadian cohorts. We evaluated different definitions of ( 1 ) immunosuppressive treatment response, ( 2 ) FRNS, including Kidney Disease Improving Global Outcomes (KDIGO) 2021 and International Pediatric Nephrology Association (IPNA) 2023 criteria, and ( 3 ) long-term remission. Outcomes were time to CKD, relapse count throughout follow-up, and time to relapse, analyzed by Cox proportional hazards and negative binomial regression. Results: We included 1114 children with nephrotic syndrome (median age at diagnosis, 3.8 years; 63% male; median follow-up, 4.7 years). Among them, 1054 (95%) were steroid sensitive, 60 (5%) were steroid resistant (steroid-resistant nephrotic syndrome [SRNS]), and 73% with SRNS achieved complete remission with steroid-sparing immunosuppression. No child with treatment-responsive SRNS developed CKD. Within 1 year of diagnosis, 281 steroid-sensitive children (27%) were classified with FRNS by KDIGO and 383 (36%) by IPNA criteria. Children with FRNS by IPNA criteria (versus KDIGO) had a similar number of relapses (adjusted rate ratio, 0.95; 95% confidence interval, 0.81 to 1.12) and CKD risk (2% each) but less often received steroid-sparing immunosuppression (hazard ratio, 0.42; 95% confidence interval, 0.32 to 0.56). Ninety-eight percent of relapses occur within 3 years of the initial diagnosis or the last relapse event. Conclusions: Children with SRNS who achieve remission have a similar CKD risk to steroid-sensitive children. Children with FRNS by IPNA 2023 and KDIGO 2021 criteria experience similar rates of relapse and CKD. This supports defining treatment resistance by response to any immunosuppressive medication, implementation of the IPNA FRNS criteria, and use of 3-year relapse-free survival as a surrogate for long-term remission.
- 15 October 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1767-1779
Challenging Clinical Practice Guideline Definitions in Childhood Nephrotic Syndrome
Key Points: Three quarters of children with steroid-resistant nephrotic syndrome respond to other immunosuppression and have good kidney outcomes. Children classified as frequently relapsing by International Pediatric Nephrology Association versus Kidney Disease Improving Global Outcomes criteria have similar relapse rates and risk of CKD. These findings support defining treatment resistance by response to any immunosuppression and implementing the International Pediatric Nephrology Association criteria for frequent relapses. Background: In childhood nephrotic syndrome, definitions of immunosuppression response, frequently relapsing nephrotic syndrome (FRNS), and long-term remission are conflicting and based on limited evidence. Our goal was to define treatment response, FRNS, and long-term remission on the basis of associated disease outcomes. Methods: We included children (6 months–18 years) diagnosed with nephrotic syndrome between 1993 and 2023 in combined Canadian cohorts. We evaluated different definitions of ( 1 ) immunosuppressive treatment response, ( 2 ) FRNS, including Kidney Disease Improving Global Outcomes (KDIGO) 2021 and International Pediatric Nephrology Association (IPNA) 2023 criteria, and ( 3 ) long-term remission. Outcomes were time to CKD, relapse count throughout follow-up, and time to relapse, analyzed by Cox proportional hazards and negative binomial regression. Results: We included 1114 children with nephrotic syndrome (median age at diagnosis, 3.8 years; 63% male; median follow-up, 4.7 years). Among them, 1054 (95%) were steroid sensitive, 60 (5%) were steroid resistant (steroid-resistant nephrotic syndrome [SRNS]), and 73% with SRNS achieved complete remission with steroid-sparing immunosuppression. No child with treatment-responsive SRNS developed CKD. Within 1 year of diagnosis, 281 steroid-sensitive children (27%) were classified with FRNS by KDIGO and 383 (36%) by IPNA criteria. Children with FRNS by IPNA criteria (versus KDIGO) had a similar number of relapses (adjusted rate ratio, 0.95; 95% confidence interval, 0.81 to 1.12) and CKD risk (2% each) but less often received steroid-sparing immunosuppression (hazard ratio, 0.42; 95% confidence interval, 0.32 to 0.56). Ninety-eight percent of relapses occur within 3 years of the initial diagnosis or the last relapse event. Conclusions: Children with SRNS who achieve remission have a similar CKD risk to steroid-sensitive children. Children with FRNS by IPNA 2023 and KDIGO 2021 criteria experience similar rates of relapse and CKD. This supports defining treatment resistance by response to any immunosuppressive medication, implementation of the IPNA FRNS criteria, and use of 3-year relapse-free survival as a surrogate for long-term remission.
- Open Access
- 24 June 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 48, 101157
Healthcare resource utilisation and costs associated with hypertension in children and adolescents: a population-based cohort study
- 24 June 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 48, 101157
Open AccessHealthcare resource utilisation and costs associated with hypertension in children and adolescents: a population-based cohort study
- 20 October 2021
- Published by Springer Nature in Current Pediatrics Reports
- Vol. 9 (4) , 104-109
Obesity in Children with Kidney Disease
- 20 October 2021
- Published by Springer Nature in Current Pediatrics Reports
- Vol. 9 (4) , 104-109
Obesity in Children with Kidney Disease
- Open Access
- 13 October 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (5) , 1105-1115
Implementing a fluid volume management program to decrease intra-dialytic hypotensive events in a paediatric in-centre haemodialysis unit: a quality improvement project
Background Intra-dialytic hypotension (IDH) is the most common serious adverse event in paediatric haemodialysis (HD). Repeated IDH results in chronic multi-organ damage and increased mortality. At the Hospital for Sick Children, Toronto, retrospective data from all in-centre HD sessions revealed frequently occurring IDH events (16.5 ± 5.6% of HD sessions per week). Based on literature review and clinical expertise, fluid volume management was selected as a potential modifiable risk factor to decrease IDH. Root causes identified as contributing to IDH were incorporated into a Paediatric haemodialysis fluid volume management (PedHDfluid) program using the Model for Improvement methodology including rapid cycles of change. Methods Multiple measures were evaluated including (i) Outcome: IDH events per number of HD sessions per week; (ii) Process: number of changes to estimated dry weight per number of HD sessions per week; (iii) Balancing: time spent on dry weight meeting per week. Data was analysed using statistical process control charts. We aimed to decrease IDH in our dialysis unit to < 10% of HD sessions per week over a 6-month period by implementing a PedHDfluid program, including a multifaceted dry weight assessment protocol, multidisciplinary meetings and electronic health records “Dry Weight Evaluation flow sheet/synopsis”. Results The project resulted in a decline in IDH events from 16.5 ± 5.6% to 8.8 ± 3.3% of HD sessions per week. More frequent dry weight changes and increased awareness of fluid removal goals were noted. Conclusions A multidisciplinary approach including regular assessment, guidelines and systematic discussion, with an embedded electronic health record assessment and data gathering tool may sustainably reduce IDH events. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 13 October 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (5) , 1105-1115
Open AccessImplementing a fluid volume management program to decrease intra-dialytic hypotensive events in a paediatric in-centre haemodialysis unit: a quality improvement project
Background Intra-dialytic hypotension (IDH) is the most common serious adverse event in paediatric haemodialysis (HD). Repeated IDH results in chronic multi-organ damage and increased mortality. At the Hospital for Sick Children, Toronto, retrospective data from all in-centre HD sessions revealed frequently occurring IDH events (16.5 ± 5.6% of HD sessions per week). Based on literature review and clinical expertise, fluid volume management was selected as a potential modifiable risk factor to decrease IDH. Root causes identified as contributing to IDH were incorporated into a Paediatric haemodialysis fluid volume management (PedHDfluid) program using the Model for Improvement methodology including rapid cycles of change. Methods Multiple measures were evaluated including (i) Outcome: IDH events per number of HD sessions per week; (ii) Process: number of changes to estimated dry weight per number of HD sessions per week; (iii) Balancing: time spent on dry weight meeting per week. Data was analysed using statistical process control charts. We aimed to decrease IDH in our dialysis unit to < 10% of HD sessions per week over a 6-month period by implementing a PedHDfluid program, including a multifaceted dry weight assessment protocol, multidisciplinary meetings and electronic health records “Dry Weight Evaluation flow sheet/synopsis”. Results The project resulted in a decline in IDH events from 16.5 ± 5.6% to 8.8 ± 3.3% of HD sessions per week. More frequent dry weight changes and increased awareness of fluid removal goals were noted. Conclusions A multidisciplinary approach including regular assessment, guidelines and systematic discussion, with an embedded electronic health record assessment and data gathering tool may sustainably reduce IDH events. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information